bpc-157 fda category 2 compounding restrictions on safety concerns Big review coming this July. Here's what athletes and patients fda restrictions bpc-157 compounding warning – FDA panel votes to place

Diabetes Metab Syndr Obes

specifically, semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1

Bacteriostatic water is sterile water that contains a small amount of preservative, typically benzyl alcohol

What they did: They transected the quadriceps (front thigh) of rats and divided them into three groups: Control, no drugs Dexamethasone, a potent corticosteroid that is known to impair healing Dexamethasone + BPC-157 What they found: Dexamethasone group: 50 % worse healing than control (confirmed negative effect of steroids) Dexamethasone + BPC-157 group: healing at the level of controls without steroids Why it matters: This is a highly clinically relevant finding

For weight management, NICE has appraised several licensed medicines that are available through NHS pathways or regulated private clinics: Semaglutide (Wegovy) NICE Technology Appraisal TA875 recommends semaglutide as an option for managing overweight and obesity in adults with a BMI of 35 kg/m or more (or 3034.9 kg/m in certain circumstances) alongside at least one weight-related comorbidity, when used within a specialist weight management service